The abstract is read at the publisher; the summary is JClub's.
Cytokine release syndrome identification and grading in immune-cell-engaging therapy trials remains inconsistent, undermining safety decisions and cross-trial comparisons despite ASTCT being the most practical standard.
- Why it matters: CRS is frequently reported, but current practices can misclassify expected immune engagement as formal syndrome, creating overly conservative escalation and premature dose-limiting toxicity calls.
- What they did: The abstract describes reporting pitfalls, including exclusion of CRS-mimicking differential diagnoses, grade 2 hypotension misclassification without formal vasoplegia testing, ASTCT’s limited organ-dysfunction scope, and misattribution of isolated transaminitis.
- The result: Addressing these gaps would help investigators, sponsors, and health authorities distinguish genuine toxicity from expected pharmacology, improving safety evaluation and trial decisions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.